Trimethyl cyclohexane-1,2,4-tricarboxylate, 98%, 250mg

N-METHYL-N-{[(2S)-OXIRAN-2-YL]METHYLMETHANESULFONAMIDE, 95.0%, 5g

2-Chloro-3-(1-pyrrolidinylcarbonyl)pyridine, 97.0%, 25g

4-{2-[4-(4,4,5,5-Tetramethyl[1,3,2]dioxaborolan-2-yl) phenoxy]ethyl}morpholine, 97.0%, 1g

N,N-Diethylnicotinamide>98.0%(GC)(T)25g

Ácido metanosulfónico, 70%, para síntesis, 2,5 L, envase de vidrio

2-AMINO-2-(OXETAN-3-YL)ACETIC ACID, 95.0%, 250mg

6,7-Dihydro-5H-cyclopenta[b]pyridin-5-one, 95.0%, 100g

Difluoro(pyridin-2-yl)acetic acid, 97.0%, 1g

5,11-Dihydro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-11-methyl-5-(2,2,2-trifluoroethyl)-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one, 98%, 100mg

4-BROMO-2-(1H-IMIDAZOL-2-YL)PHENOL, 95.0%, 100mg

(R)-3-(6-Ethoxy-pyrimidin-4-ylamino)-pyrrolidine-1-carboxylic acid tert-butyl ester, 95.0%, 250mg

2-Chloro-6-methyl-7H-pyrrolo[2,3-d]pyrimidine, 95.0%, 250mg